^
    Back
    Association details:
    Biomarker:MLL rearrangement
    Cancer:Acute Myelogenous Leukemia
    Drug:ziftomenib (KO-539) (Menin-MLL inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML

    Excerpt:
    ......
    Trial ID:
    KOMET-007
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Excerpt:
    ......
    Trial ID:
    NCT06001788
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Kura Oncology Press Release
    Title:

    Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting

    Published date:
    12/05/2020
    Excerpt:
    Kura Oncology, Inc...announced preliminary clinical data from KOMET-001, an ongoing Phase 1/2A clinical trial...A patient with a KMT2A/MLL rearrangement had a marked decrease in hydroxyurea requirements and attained peripheral blood count stabilization at the 50 mg starting dose.